Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > International licensing expert Peter Turvey joins Starpharma Board

Abstract:
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced the appointment of Mr Peter Turvey to the Board of Directors. Mr Turvey recently retired from CSL (ASX:CSL) as Executive Vice President Licensing for the R&D Division and Company Secretary after nearly two decades.

International licensing expert Peter Turvey joins Starpharma Board

Melbourne, Australia | Posted on March 8th, 2012

Mr Turvey brings to the Starpharma Board exceptional commercial licensing skills having worked at CSL since 1992 in various roles including Group General Counsel, Company Secretary and Executive Vice President Licensing.

Mr Turvey played a key role in the transformation of CSL from a government owned enterprise, through listing in 1994, to a global plasma and biopharmaceutical company. He led the management of CSL's intellectual property across CSL's entire operations, managing a large patent portfolio, and a global intellectual property team.

Among the many licensing deals he was involved with, the most significant included the Gardasil license to Merck & Co., the licensing of the Iscomatrix® adjuvant platform technology to the world's leading vaccine manufacturers, and establishment of the P.gingivalis vaccine technology collaboration between the CRC for Oral Health and Sanofi-Pasteur.

With a strong partnering model at the core of Starpharma's product development and with multiple products nearing market, Mr Turvey's skills and experience will be invaluable to the Board and Management of Starpharma.

Chairman of the Board, Mr Peter Bartels said: "We are very pleased to welcome Peter to the Board of Starpharma and believe his skills and experience are highly complementary to that of our existing board. We welcome Peter's experience and industry insights as we near the final stages of commercialisation for many of our products."

Mr Turvey added: "Since retiring from CSL, I was keen to remain active in a leading biopharmaceutical company and was excited and impressed at the depth and breadth of the Starpharma portfolio, the company's Management Team and significant opportunity to contribute to this business at a time where there are multiple market opportunities.

"I think the Board and Management have done a wonderful job to date to set the Company up for great success and I really look forward to contributing to that ongoing success."

Mr Turvey was appointed to the Board of AusBiotech last year and has also recently joined the Foursight Group as a Principal.

The appointment is effective from 19 March 2012.

####

About Starpharma Holdings Limited
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the development of dendrimer products for pharmaceutical, life science and other applications.

Starpharma’s underlying technology is built around dendrimers – a type of synthetic nanoscale polymer that is highly regular in size and structure and well suited to pharmaceutical uses. Starpharma has three core development programs: VivaGel® portfolio, drug delivery and agrochemicals with the Company developing a number of products internally and others via commercial partnerships. In addition, products for diagnostics and laboratory reagents are already on market through licence arrangements with partners including Siemens Healthcare and Merck KGaA.

Starpharma’s lead product is VivaGel® (SPL7013 Gel), a gel-based formulation of a proprietary dendrimer. VivaGel® is under clinical development for the treatment and prevention of bacterial vaginosis (BV) and also as a vaginal microbicide to prevent the transmission of sexually transmitted infections including HIV and genital herpes.

Starpharma has also signed separate licence agreements with Ansell Limited (ASX:ANN) and Okamoto Industries Inc (TSE) to market a value-added, VivaGel® -coated condom. Ansell manufactures and sells leading condom brands worldwide, including Lifestyles®, ZERO® and SKYN®. Okamoto is the market leader for condoms sold in Japan, the world’s second largest condom market.

In the wider pharmaceutical and life science fields, Starpharma has both partnered and internal programs in Drug Delivery. Most recently Starpharma announced pre-clinical results in its Docetaxel (Taxotere®) program demonstrating significant improvements in that agent’s anticancer efficacy and the enhancement of solubility offering potential safety benefits as well. The company is also exploring dendrimer opportunities in agrochemicals in a series of industry partnerships as well as with internal programs including an enhanced version of glyphosate (the active ingredient in Roundup®).

For more information, please click here

Contacts:
TOM DONOVAN
Senior Account Executive

Copyright © Starpharma Holdings Limited

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Picosun patents ALD nanolaminate to prevent electronics from overheating September 28th, 2016

Leti and Taiwanese Tech Organizations Sponsoring Workshop in Taipei on MEMS, IoT, Smart Lighting Applications, System Reliability & Security September 28th, 2016

Fighting cancer with sticky nanoparticles September 27th, 2016

Gold nanoparticles conjugated quercetin inhibits epithelial-mesenchymal transition, angiogenesis and invasiveness via EGFR/VEGFR-2 mediated pathway in breast cancer September 27th, 2016

Nanomedicine

Fighting cancer with sticky nanoparticles September 27th, 2016

Gold nanoparticles conjugated quercetin inhibits epithelial-mesenchymal transition, angiogenesis and invasiveness via EGFR/VEGFR-2 mediated pathway in breast cancer September 27th, 2016

Tattoo therapy could ease chronic disease: Rice-made nanoparticles tested at Baylor College of Medicine may help control autoimmune diseases September 23rd, 2016

BBI Solutions launches innovative conjugate blocking technology that enhances signal intensity for lateral flow immunoassays September 20th, 2016

Announcements

Picosun patents ALD nanolaminate to prevent electronics from overheating September 28th, 2016

Leti and Taiwanese Tech Organizations Sponsoring Workshop in Taipei on MEMS, IoT, Smart Lighting Applications, System Reliability & Security September 28th, 2016

Fighting cancer with sticky nanoparticles September 27th, 2016

Gold nanoparticles conjugated quercetin inhibits epithelial-mesenchymal transition, angiogenesis and invasiveness via EGFR/VEGFR-2 mediated pathway in breast cancer September 27th, 2016

Patents/IP/Tech Transfer/Licensing

Picosun patents ALD nanolaminate to prevent electronics from overheating September 28th, 2016

NIST Patents Single-Photon Detector for Potential Encryption and Sensing Apps September 16th, 2016

For first time, carbon nanotube transistors outperform silicon September 8th, 2016

Industrial Nanotech, Inc. Provides Shareholder Update August 22nd, 2016

Appointments/Promotions/New hires/Resignations/Deaths

Dr Barbara Armbruster promoted to Worldwide Sales and Marketing Director for XEI Scientific September 27th, 2016

Dr Barbara Armbruster joins XEI Scientific as Marketing Director June 1st, 2016

Park Systems Global Expansion in AFM Market Includes Appointment of New Executives April 23rd, 2016

GLOBALFOUNDRIES Adds Alain Mutricy as Head of Product Management Group March 3rd, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic